Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorPALICH, R.
dc.contributor.authorGHOSN, J.
dc.contributor.authorCHAILLON, A.
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOILET, Valerie
dc.contributor.authorNERE, M. L.
dc.contributor.authorCHAIX, M. L.
dc.contributor.authorDELOBEL, P.
dc.contributor.authorMOLINA, J. M.
dc.contributor.authorLUCHT, F.
dc.contributor.authorBOUCHAUD, O.
dc.contributor.authorRIEUX, V.
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHIEBAUT, Rodolphe
dc.contributor.authorLEVY, Y.
dc.contributor.authorDELAUGERRE, C.
dc.contributor.authorLELIEVRE, J. D.
dc.date.accessioned2020-07-09T08:12:32Z
dc.date.available2020-07-09T08:12:32Z
dc.date.issued2019-02-01
dc.identifier.issn1473-5571 (Electronic) 0269-9370 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/10243
dc.description.abstractEnOBJECTIVES: This study aimed to determine the timing and level of HIV rebound in blood and seminal plasma and to characterize the HIV rebounding populations after antiretroviral treatment interruption (ATI) in HIV-1-infected participants enrolled in a therapeutic vaccine trial. DESIGN: A twelve-week (W) ATI period was proposed at W36 to patients enrolled in the VRI02/ANRS149-LIGHT trial. Paired blood and semen samples were collected before (W32 or W36) and during ATI (W38, W40, W42, W44 and W48). METHODS: HIV-RNA and HIV-DNA were quantified sequentially from blood and semen samples. Ultradeep sequencing (UDS, Roche/454) of partial env HIV-DNA/RNA (C2V3) was performed in both compatments. RESULTS: HIV-RNA rebounded in blood plasma and seminal plasma of all ten participants after ATI (median peak of 5.12 log10 cp/ml [range: 4.61-6.35] and 4.26 log10 cp/ml [3.20-4.67], respectively). HIV-RNA rebound was detected in blood plasma as soon as W38 in 8/10 patients, and in seminal plasma between W38 and W40 in 8/10 patients. Phylogenetic approaches showed intermingled HIV-RNA populations from plasma and semen during ATI, suggesting a lack of viral compartmentalization between blood and semen. CONCLUSION: Our data demonstrate rapid and high HIV rebound in semen after ATI, raising concerns about high risk of HIV sexual transmission during HIV cure trials.
dc.language.isoENen_US
dc.subject.enSISTM
dc.title.enViral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial
dc.title.alternativeAIDSen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/qad.0000000000002058en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30325777en_US
bordeaux.journalAIDS. Official journal of the international AIDS Societyen_US
bordeaux.page279-284en_US
bordeaux.volume33en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamSISTM_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03161003
hal.version1
hal.date.transferred2021-03-08T14:34:31Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=AIDS.%20Official%20journal%20of%20the%20international%20AIDS%20Society&rft.date=2019-02-01&rft.volume=33&rft.issue=2&rft.spage=279-284&rft.epage=279-284&rft.eissn=1473-5571%20(Electronic)%200269-9370%20(Linking)&rft.issn=1473-5571%20(Electronic)%200269-9370%20(Linking)&rft.au=PALICH,%20R.&GHOSN,%20J.&CHAILLON,%20A.&BOILET,%20Valerie&NERE,%20M.%20L.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée